Apply

Ready to go for it?

AI Apply speeds things up—apply directly if you prefer.

FREE ACCESS
5,000–10,000 jobs/day
Scoutfield Logo

See all jobs on Scoutfield

Search thousands of fresh jobs every day.

Discover
  • Fresh listings
  • Fast filters
  • No subscription required
Create a free account and start exploring right away.
ICON plc

Senior Director, Drug Development Services – Cardiometabolic

ICON plc

. Lead strategic Cardiometabolic drug development design and deliver tailored, asset-focused solutions across liver diseases .

Posted 11/3/2026full-timeRemote • United StatesSenior💰 $195,808 - $244,760 per yearWebsite

Core Competencies

Role fit
Core Competencies

Use this summary to align your resume positioning with the role.

Demonstrates deep expertise in Cardiometabolic and liver disease drug development, with a strong focus on clinical trial design and strategic stakeholder engagement. Capable of providing high-level scientific input and mentorship while fostering innovation in drug development.

Highest-signal resume keywords
Cardiometabolic Drug DevelopmentClinical Trial DesignStakeholder EngagementCross-Functional LeadershipMD with Cardiometabolic Specialization

ATS Keywords

Tailor your resume
Applicant Tracking System Keywords

Tip: use these terms in your resume and cover letter to boost ATS matches.

Hard Skills
Protocol DevelopmentBiomarkersEndpointsFibrosis StagingHistologic MarkersNon-Invasive MarkersTherapeutic LandscapesData InterpretationProposal DevelopmentStudy Strategy
Soft Skills
Excellent CommunicationPresentation SkillsCollaborative MindsetMentorshipThought Leadership
Certifications & Qualifications
MD
Industry Keywords
CardiometabolicLiver DiseaseClinical ResearchPharmaceuticalKOL Engagement

About the role

Key responsibilities & impact
  • Lead strategic Cardiometabolic drug development design and deliver tailored, asset-focused solutions across liver diseases
  • Own end-to-end protocol development, including design, scientific review, and evaluation for Phase I–IV clinical trials
  • Advise senior client stakeholders on Cardiometabolic development strategy and data interpretation
  • Lead proposal development, study strategy, and bid defense activities
  • Build and maintain relationships with Cardiometabolic KOLs, advisory boards, and regulatory authorities
  • Develop Cardiometabolic-focused service offerings and support innovation and growth in liver disease drug development
  • Provide training, mentorship, and thought leadership to internal teams and external partners
  • Participate in portfolio reviews, governance discussions, and scientific oversight
  • Support operational teams with high-level scientific input, investigator meetings, and study discussions
  • Represent ICON at Cardiometabolic congresses and scientific forums

Requirements

What you’ll need
  • Deep, recognized expertise in Cardiometabolic and liver disease drug development
  • Strong understanding of Cardiometabolic clinical trial design, biomarkers, endpoints, fibrosis staging, histologic and non-invasive markers, and evolving therapeutic landscapes
  • Proven ability to operate in a strategic, client-facing, consultative environment within pharmaceutical or clinical research settings
  • Experience engaging and influencing senior scientific and clinical stakeholders across industry and academia
  • Excellent communication and presentation skills, with ability to translate complex Cardiometabolic data into actionable development insights
  • Collaborative, global mindset with strong cross-functional leadership capability
  • MD required, ideally with specialization or substantial clinical/research experience in Cardiometabolic diseases
  • Legal right to work in the country where the role is based

Benefits

Comp & perks
  • Competitive base salary and performance related incentives
  • Medical, dental, and vision coverage where applicable
  • Retirement and pension plans
  • Life assurance and disability coverage
  • Employee assistance programmes and wellbeing resources
  • Learning and development opportunities through structured training and career pathways
  • 20–40% domestic and international travel opportunity
  • Highly visible, impact-driven role shaping the future of Cardiometabolic drug development